Evolution of the index of activity in patients with systemic sclerosis treated with cyclophosphamide and prednisone
Keywords:
systemic sclerosis, therapeutic, index of activityAbstract
Introduction: The systemic sclerosis is an autoimmune disease of the connective tissue where the vasculopathy happens initially and persist during all the disease. The immune component starts since the inflammatory process triggers off but he diminishes until you dwell on the evolutionary course and it is substituted for fibrosis, this ends pathogenic acquires great significance in the process. The index of activity reveals a critical period of the disease.
Objective: Evaluating patients' clinical evolution of the index of activity with systemic sclerosis with the applied therapeutics.
Methods: The study was quasi-experiences (or secondary prevention). In order to determine if the therapeutic applied scheme decreases symptomatology of its systemic activity. You started in March of the 2013 to March of the 2016, with duration of 24 months. They were 31 patients that split into two groups according to the clinical stages obtained of Comprehensive Development Index. In the group to (clinical stages I and II) 16 patients and in the group B (clinical stages III and IV) 15 patients. The evolution evaluated according to variables of the instrument of evaluation the start, to the six and 12 months itself of once the therapeutic scheme was applied. The T utilized the proof itself, or exact Fisher's proof when moral values were all the same or minor to three, the statistical significance determined in p≥ 0.05 itself. The calculation of the stocking, percentage analysis, and Wilcoxon's proof to know the relation of variables through the time.
Results: The therapeutic applied scheme, previous validation, you improved the index of activity of the patients of both groups A and B that is in clinical premature and overdue stages. In the activity moderated for the group A statistical significance for system microvascular (0.023) and respiratory (0.025) to the six months, and to the 12 months’ skin (0.023) and microvascular (0.006). For the intense activity significant improvement to the six months for muscleskelettic (0.005) and rheumatoid positive factor (0.008), to the 12 months’ significant improvement for muscleskelettic (0.004); and examine of laboratory like erythrocyte sedimentation rate (0.008) circulating immune complexes (0.005), and rheumatoid factor (0.003). For the group B in the moderate activity significant improvement for respiratory system existed (0.014), and cardiovascular (0.020) that kept to the 12 months, added up its digestive system (0.008). Evident level improvement of skin (0.004), circulating immune complexes (0.008) and rheumatoid factor were caught up within the intense activity to the 12 months (0.014).
Conclusions: Improvement in the index of activity of patients with systemic sclerosis, with the therapeutic scheme applied, with clinical stability and humoral from initial stages of the disease was caught up with.
Downloads
References
Fériz AR, Louis MR, Espinoza RL, Khamashta M, Cerinic MM, Sanmartí R, et al. Enfermedades inflamatorias reumatológicas. ed. Producciones científicas Ltda. PANLAR, 2016; cap.18. p.397-419.
Remedios Batista SE, Montada Cedeño E, Del Campo Avilés E, Torres Pérez L, Fernández Portelles A, et. al. Mecanismos etiopatogénicos en la esclerosis sistémica. CCM [Internet]. 2016 [citado 2019 Junio 22]; 20(1): [aprox 11 p.] Disponible en: http://www.revcomed.sld.cu.
Remedios Batista SE, Montada Cedeño E, Rivas Carralero R. Caracterización clínica epidemiológica de pacientes con esclerosis sistémica en Holguín. Rev Cub de Reuma [Internet]. 2018 [citado 2019 Abr. 30]; 20(1). Disponible en: http://www.revreumatologia.sld.cu/.
Vonk MC, Van den Hoogen, Van Riel PL, Valentini G. What does the clinician need to improve patient care in systemic sclerosis? Validated clinimetric criteria, useful in the early phase of systemic are lacking. Ann Rheum Dis [Internet]. 2007 [Citado 2018 May 23]; 66:1129–1131. Disponible en: www.annrheumdis.com.
Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, Reyes García D. Estadios clínicos en pacientes con esclerosis sistémica en Holguín. (Original). ISSN: 1817-5996. Rev. Cub.[Internet] 2018[Citado 2019 Dic 23]; 20(2). Disponible en: http://www.revreumatologia.sld.cu/.
Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, del Campo Avilés E, Torres Pérez L. Validación de los expertos acerca de la conducta terapéutica a seguir con los pacientes con esclerosis sistémica. Rev. Cuba Reumatol [Internet] 2018 Dic [citado 2020 Abr 30]; 20(3): e605. Disponible en: http://scieloprueba.sld.cu.
Reyes Llerena GA, Guibert Toledano ZM, López Cabreja G, Hernández Derivet C, et al. Esclerosis sistémica. Evaluación clínico-epidemiológica de una serie de casos en dos centros de referencia en Cuba [internet]. 2014 [Citada 2020 Marzo 23]; 6(1): [Aprox 12 p.]. Disponible en: http://www.revreumatologia.sld.cu.
Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. Semin Arthritis Rheum. [Internet]. 2017 [citada 2020 En 12]; 46 (6) 767-774. Disponible en:http://www.ncbi.nlm.nih.gov/pubmed.
Hachulla E, Bagou G, Ganansia O, Lefort H, Leroy C. Esclerodermia sistémica [Internet]. Francia: Centros de Referencias de Enfermedades Raras; 2017 [Citado en Abril 25 2020]. Disponible en: http://www.orpha.net/data/patho/Emg/Int/es/Esclerodermia_ES_es_EMG_ORPHA801.pdf
Remedios Batista SE, Rivas Carralero R, Montada Cedeño E, del Campo Avilés E, Pérez Torres L, Caselles Fajardo HL. Supervivencia en pacientes con esclerosis sistémica en la provincia de Holguín Rev. Cub. Reumatol [Internet]. 2017 [Citado 22 Agosto 2017]; 19(2): [aprox 1]. Disponible en: http://www.revreumatologia.sld.cu.
Hernández Negrín H. ¿Son las arritmias un predictor de mortalidad en pacientes holguineros con esclerosis sistémica? Rev. Cub. Reumatol [Internet]. 2017 [Citado 22 Octubre 2017]; 19(3): [aprox 1]. Disponible en: http://www.revreumatologia sld.cu.
Schlabs M, Pawlak-Buś K, Leszczyński. Retrospective analysis of infection prevalence in patients with progressive systemic sclerosis treated with cyclophosphamide. Journal of Medical Science [Internet]2015 [Citado 25 Abril 2019]; 3(84):44-56. Disponible en: http://www.jrheum.org.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med [Internet] 2016 [Citado 2019 Abr. 30]; 4(9):708-719. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/.
HoylesRK,EllisRW,Wellbury S, et al.A multicenter prospective ramdomized,doublé blind placebo-contolled trial of corticosteroids and intravenous ciclophosphamide followed by oral azhatioprine for the treatment of pulmonary fibrosis in Scleroderma.Arthritis Rheum. 2006.54:3962-3970.
Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L.et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) Ann Rheum Dis. [Internet] 2017 [citada 2019 Abr 12]; 76:1207–1218. Disponible en: http://ard.bmj.com.
Hassan ML; Sociedad Argentina de Dermatología. Consenso sobre esclerodermia. Actualización 2015.[Internet] 2015
[Citado 25 Abril 2020], Disponible en: http://ard.bmj.com.http://www.sad.org.ar/wp-content/uploads/2016/04/CONSENSO-ESCLERODERMIA.pdf
Masuii Y, Asano Y, Takahashi T, Shibata S, Akamata, et.al. Clinical significance of monitoring serum adiponectin levels during intravenous pulse CYC therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatology [Internet] 2013 [Citado 25 Abril 2020]; 23(2):[aprox1].Disponible en: http://www.ncbi.nln.nih.gov/pubmed?.
Pérez Campos D, Estévez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Rheumatol. Clin [Internet]. 2012 [Citado 23 Mar 2018]; 8(2):58-62. Disponible en: http://www.elsevier.es/en/linksolver/pdf/pii/s1699-.
Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. [Internet]. 2003 [Citado 23 Dic. 2019]; 22(4): [aprox 1]. Disponible en: http://dx.doi.org/10.1007/s10067-003-0733-2.
Graña D, Vargas A, Bèrez A, Goñi M, Danza A. Esclerosis sistémica: forma de presentación y manejo terapéutico. Experiencia de un grupo de trabajo en Enfermedades Autoinmunes Sistémicas. Rev. Urug. Med. Interna [Internet]. 2018 [citada 2019 Abr 30]; 1:15-22. Disponible en: http://www.scielo.edu.uy/pdf/rumi/v3n1/2393-6797-rumi-3-01-15.pdf.
Mendoza FA, Nagle SJ, Lee JB, Jiménez SA. A prospective observational study of Mycophenolate Mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J. Rheumatol [Internet]. 2012 [Citado 25 Abril 2020]; 39(6):1241- 47. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed?
Volkmann ER, Tashkin DP, Li N, Roth MD, and Khanna D, Hoffmann-Vold AM, et al. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol [Internet]. 2017 Jul [Citado 23 feb. 2020]; 69(7):1451-1460. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/.
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
